Skip to Main Content

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Conditions

Diseases of the Nervous System

Phase II

What is the purpose of this trial?

The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281 administered to participants with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing standard of care therapy.

  • Trial with
    Momenta Pharmaceuticals, Inc.
  • Start Date
    04/23/2019
  • End Date
    01/30/2020
Trial Image

For more information about this study, contact:

Bailey Munro Sheldon

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/03/2019
  • Study HIC
    #2000024853